Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Form of Alpha1-Antitrypsin (AAT) From the European Commission
Trends in the Diagnosis of Symptomatic Patients With Alpha-1 Antitrypsyn Deficiency Between 1968 and 2003
Announcing the Launch of Talecris Biotherapeutics: Combining a Proud History of Patient Care with a Bold New Vision
Home | Patient Services | Reference Guide | For The Medical Community | Newsletter | Multimedia | Contact Us
Designed and Maintained by Innovative Internet Solutions.